Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Noboru Ideno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4745-8417; OpenAlex author ID A5027474110. Sources: OpenAlex.

Their work

Papers
28 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
81
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: 3 papers · 2026: 3 papers

Papers 28

  1. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  2. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. First author DOI 10.1016/j.surg.2026.110423↗
  3. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  4. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  5. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.108958↗
  6. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
  7. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. First author DOI 10.1002/deo2.333↗
  8. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  9. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  10. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  11. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Co-author DOI 10.1007/s00464-023-10438-7↗
  12. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  13. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-023-05591-2↗
  14. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. Co-author DOI 10.1245/s10434-023-13936-z↗
  15. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Co-author DOI 10.1007/s00423-022-02453-4↗
  16. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s12672-021-00462-1↗
  17. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  18. Early Detection of Pancreatic Cancer: Role of Biomarkers in Pancreatic Fluid Samples. Co-author DOI 10.3390/diagnostics10121056↗
  19. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. Co-author DOI 10.1038/s41374-018-0171-z↗
  20. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  21. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
  22. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗
  23. Role of ERCP in the era of EUS-FNA for preoperative cytological confirmation of resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-014-0845-0↗
  24. Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary m… Co-author DOI 10.1016/j.surg.2013.06.059↗
  25. Profiling of autoantibodies in sera of pancreatic cancer patients. Co-author DOI 10.1245/s10434-014-3574-0↗
  26. Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm … First author DOI 10.1007/s00534-012-0541-7↗
  27. A minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma using biomarkers in duodenal juice. Co-author DOI 10.1097/mpa.0b013e3182649979↗
  28. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal pa… Co-author DOI 10.6092/1590-8577/1494↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 14 shared papers, 2022–2026 · strength 2.53
  2. Naoki Ikenaga · 13 shared papers, 2022–2026 · strength 2.30
  3. Toshiya Abe · 12 shared papers, 2022–2026 · strength 2.13
  4. Kenoki Ohuchida · 12 shared papers, 2013–2026 · strength 1.80
  5. Yoshinao Oda · 15 shared papers, 2013–2026 · strength 1.70
  6. Takao Ohtsuka · 15 shared papers, 2013–2026 · strength 1.54
  7. Masafumi Nakamura · 12 shared papers, 2013–2025 · strength 1.45
  8. Chika Iwamoto · 5 shared papers, 2022–2025 · strength 0.82
  9. Masafumi Nakamura · 4 shared papers, 2022–2025 · strength 0.76
  10. Yasuhisa Mori · 8 shared papers, 2013–2025 · strength 0.75
  11. Kousei Ishigami · 5 shared papers, 2013–2025 · strength 0.73
  12. So Nakamura · 4 shared papers, 2023–2024 · strength 0.69
  13. Tomohiko Shinkawa · 4 shared papers, 2022–2025 · strength 0.65
  14. Nobuhiro Fujita · 3 shared papers, 2023–2025 · strength 0.57
  15. Masao Tanaka · 10 shared papers, 2013–2026 · strength 0.56
  16. Chikanori Tsutsumi · 3 shared papers, 2024–2025 · strength 0.53
  17. Koki Oyama · 3 shared papers, 2024–2025 · strength 0.53
  18. Masatoshi Murakami · 3 shared papers, 2022–2025 · strength 0.52
  19. Nao Fujimori · 3 shared papers, 2022–2025 · strength 0.52
  20. Yuki Mochida · 3 shared papers, 2022–2025 · strength 0.50
  21. Yusuke Watanabe · 4 shared papers, 2015–2025 · strength 0.48
  22. Masataka Hayashi · 3 shared papers, 2023–2024 · strength 0.48
  23. Mamoru Takenaka · 2 shared papers, 2026 · strength 0.46
  24. Keiji Hanada · 2 shared papers, 2026 · strength 0.46
  25. Masayuki Kitano · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.